XORTX Therapeutics Inc.

NasdaqCM:XRTX Stock Report

Market Cap: US$3.6m

XORTX Therapeutics Past Earnings Performance

Past criteria checks 0/6

XORTX Therapeutics has been growing earnings at an average annual rate of 12.3%, while the Pharmaceuticals industry saw earnings growing at 10.7% annually.

Key information

12.25%

Earnings growth rate

37.10%

EPS growth rate

Pharmaceuticals Industry Growth5.95%
Revenue growth raten/a
Return on equity-215.46%
Net Marginn/a
Last Earnings Update31 Mar 2026

Recent past performance updates

No updates

Recent updates

Seeking Alpha • Sep 19

XORTX completes positive pre-phase 3 meeting with the FDA

XORTX Therapeutics (NASDAQ:XRTX) said it had completed the previously announced Type B Pre-phase 3 meeting with the U.S. Food and Drug Administration for XRx-008 program for the treatment of autosomal dominant polycystic kidney disease. Ahead of the meeting with the FDA, the Pre-Phase 3 Briefing Package provided an up-to-date summary of the work completed for the XRx-008 program, including updates regarding chemistry, manufacturing, pharmacology, toxicology, clinical results to date, and regulatory and clinical plans. The company said the FDA reviewed the package of data and responded with minimal comments on the work accomplished to date and focused their feedback on XORTX clinical planning. The FDA's focus of the meeting was on optimizing trial design. "A particularly valuable aspect of FDA advice was an emphasis on how the Company might gain market approval with a single phase 3 registration trial to demonstrate efficacy and safety," the company added. XORT has risen 1.5% before the bell.
Seeking Alpha • Aug 22

Xortx stock soars 40% as kidney disease drug shows promise in bridging study

Xortx Therapeutics (NASDAQ:XRTX) said its proprietary formulation of oxypurinol showed a substantial increase in oral bioavailability provided with food compared to the fasted state in a pharmacokinetics bridging study, dubbed XRX-OXY-101, Part 2. The company added that the trial also showed a clean safety and pharmacologic profile with no drug related adverse or serious adverse events related to oral administration of oxypurinol. XRX-OXY-101 bridging pharmacokinetic study is designed with four important objectives, the company noted in an Aug. 22 press release. "Successful completion of Part 1 and now part 2 of the XRX-OXY-101 study provides key data and knowledge for selecting the clinical dose and formulation for future oral dosing for our planned phase 3 registration trial in ADPKD," said Xortx CEO Allen Davidoff. The company's planned phase 3 trial in autosomal dominant polycystic kidney disease (ADPKD) expects to begin patient dosing in H1 2023. XRTX +40.40% to $2.12 premarket Aug. 22
Seeking Alpha • Jul 13

XORTX jumps over 100% after early encouraging data for rare disease therapy

Nano-cap pharma XORTX Therapeutics (NASDAQ:XRTX) surged ~103% on above average volume in the pre-market Wednesday after the company announced encouraging results for its oxypurinol formulation from a pharmacokinetics bridging study. The trial XRX-OXY-101 was the Part 1 of the three-part pharmacokinetics bridging study conducted ahead of a Phase 3 registration trial in autosomal dominant polycystic kidney disease (“ADPKD”), a rare disease that affects more than 10M globally. According to topline data, two versions of XORTX’s (XRTX) oxypurinol formulation was found to have a substantial increase in oral bioavailability compared to a control, the company said. In addition, the oral administration of oxypurinol showed a clean safety and pharmacologic profile with no drug related adverse or serious adverse events, XORTX (XRTX) added. Last week, the company requested a type B Pre-Phase 3 meeting with the FDA, in connection with its clinical development of an ADPKD therapy.

Revenue & Expenses Breakdown

How XORTX Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqCM:XRTX Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 260-320
31 Dec 250-321
30 Sep 250-221
30 Jun 250-221
31 Mar 250-120
31 Dec 240-320
30 Sep 240-120
30 Jun 240-121
31 Mar 240-321
31 Dec 230-222
30 Sep 230-724
30 Jun 230-725
31 Mar 230-726
31 Dec 220-827
30 Sep 220135
30 Jun 220-324
31 Mar 220-223
01 Jan 220-221
30 Sep 210-910
30 Jun 210-310
31 Mar 210-310
31 Dec 200-110
30 Sep 200-110
30 Jun 200-100
31 Mar 200000
31 Dec 190000
30 Sep 190000
30 Jun 190-100
31 Mar 190-100
31 Dec 180-310
30 Sep 180-310
30 Jun 180-310
31 Mar 180-310
31 Dec 170000
30 Sep 170000
30 Jun 170000
31 Mar 170000
31 Dec 160000

Quality Earnings: XRTX is currently unprofitable.

Growing Profit Margin: XRTX is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: XRTX is unprofitable, but has reduced losses over the past 5 years at a rate of 12.3% per year.

Accelerating Growth: Unable to compare XRTX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: XRTX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-4.8%).

Return on Equity

High ROE: XRTX has a negative Return on Equity (-215.46%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/07 09:32
End of Day Share Price 2026/07/07 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

XORTX Therapeutics Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners